BACKGROUND: Pilot studies of interferon alpha (IFN-alpha) suggest a high remission rate in the treatment of active ulcerative colitis. We evaluated the safety of pegylated interferon alpha (PegIFN) and its role in induction of remission in patients with active ulcerative colitis, in a multicentre placebo controlled trial. METHODS:Sixty patients with a clinical activity score (CAI) of >6 were randomised to receive placebo (n=20), PegIFN 0.5 microg/kg (n=19), or PegIFN 1.0 microg/kg body weight (n=21) once weekly (PegIntron; Schering-Plough, USA) over 12 weeks. Patients receiving 5-aminosalicylates, steroids, and/or azathioprine in stable dosages were included. RESULTS:Serious adverse events were seen in none of the placebo patients, in 3/19 patients in the PegIFN 0.5 microg/kg group (hospitalisation due to disease flare up n=3), and in 3/21 in the PegIFN 1.0 microg/kg group (hospitalisation due to disease flare up n=1; thrombosis n=1; grand mal seizure n=1). Otherwise, we observed only minor IFN-alpha side effects. Clinical remission rates at week 12 (CAI < or =4) were 7/20 (35%) in the placebo, 9/19 (47%) in the PegIFN 0.5 microg/kg group, and 7/21 (33%) in the PegIFN 1.0 microg/kg group (NS). Early withdrawal from the study was observed in 11/20 placebo patients, in 6/19 in the PegIFN 0.5 microg/kg group, and in 10/21 in the PegIFN 1.0 microg/kg group, mainly due to lack of efficacy. The higher PegIFN dose was associated with a significant decrease in levels of C reactive protein (p=0.003, day 0 v 85). CONCLUSIONS: PegIFN is safe but not effective, at the dosages used, in patients with ulcerative colitis.
RCT Entities:
BACKGROUND: Pilot studies of interferon alpha (IFN-alpha) suggest a high remission rate in the treatment of active ulcerative colitis. We evaluated the safety of pegylated interferon alpha (PegIFN) and its role in induction of remission in patients with active ulcerative colitis, in a multicentre placebo controlled trial. METHODS: Sixty patients with a clinical activity score (CAI) of >6 were randomised to receive placebo (n=20), PegIFN 0.5 microg/kg (n=19), or PegIFN 1.0 microg/kg body weight (n=21) once weekly (PegIntron; Schering-Plough, USA) over 12 weeks. Patients receiving 5-aminosalicylates, steroids, and/or azathioprine in stable dosages were included. RESULTS: Serious adverse events were seen in none of the placebo patients, in 3/19 patients in the PegIFN 0.5 microg/kg group (hospitalisation due to disease flare up n=3), and in 3/21 in the PegIFN 1.0 microg/kg group (hospitalisation due to disease flare up n=1; thrombosis n=1; grand mal seizure n=1). Otherwise, we observed only minor IFN-alpha side effects. Clinical remission rates at week 12 (CAI < or =4) were 7/20 (35%) in the placebo, 9/19 (47%) in the PegIFN 0.5 microg/kg group, and 7/21 (33%) in the PegIFN 1.0 microg/kg group (NS). Early withdrawal from the study was observed in 11/20 placebo patients, in 6/19 in the PegIFN 0.5 microg/kg group, and in 10/21 in the PegIFN 1.0 microg/kg group, mainly due to lack of efficacy. The higher PegIFN dose was associated with a significant decrease in levels of C reactive protein (p=0.003, day 0 v 85). CONCLUSIONS:PegIFN is safe but not effective, at the dosages used, in patients with ulcerative colitis.
Authors: S M Madsen; P Schlichting; B Davidsen; O H Nielsen; B Federspiel; P Riis; P Munkholm Journal: Am J Gastroenterol Date: 2001-06 Impact factor: 10.864
Authors: A Kaser; D Novick; M Rubinstein; B Siegmund; B Enrich; R O Koch; W Vogel; S H Kim; C A Dinarello; H Tilg Journal: Clin Exp Immunol Date: 2002-08 Impact factor: 4.330
Authors: S B Hanauer; M Robinson; R Pruitt; A J Lazenby; T Persson; L G Nilsson; K Walton-Bowen; L P Haskell; J G Levine Journal: Gastroenterology Date: 1998-09 Impact factor: 22.682
Authors: H Tilg; J W Mier; W Vogel; W E Aulitzky; C J Wiedermann; E Vannier; C Huber; C A Dinarello Journal: J Immunol Date: 1993-05-15 Impact factor: 5.422
Authors: Peter J Mannon; Ronald L Hornung; Zhiqiong Yang; Chuli Yi; Catherine Groden; Julia Friend; Michael Yao; Warren Strober; Ivan J Fuss Journal: Gut Date: 2010-10-22 Impact factor: 23.059
Authors: V Wu; A A Smith; H You; T A Nguyen; R Ferguson; M Taylor; J E Park; P Llontop; K R Youngman; T Abramson Journal: Mucosal Immunol Date: 2015-10-14 Impact factor: 7.313
Authors: M Higashiyama; R Hokari; C Kurihara; T Ueda; M Nakamura; S Komoto; Y Okada; C Watanabe; A Kawaguchi; S Nagao; S Miura Journal: Clin Exp Immunol Date: 2010-08-19 Impact factor: 4.330